Program
itepekimab
Also written as “Itepekimab (SAR440340)”, “REGN3500” and “Itepekimab SAR440340”.
Its studies are mostly in Nasal Polyps · Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · Bronchiectasis, led by 2 companies.
Drug pageItepekimab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 123 open or running | phase 3since Dec 30, 2020 | Dec 15, 2017 | Feb 17, 2027phase 3 · NCT07424144 |
| Regeneron Pharmaceuticals | 50 open or running | phase 2since Nov 7, 2018 | Oct 25, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 25, 2016First study: phase 1 study in Healthy VolunteersFirst studyNCT02958436 · 40 enrolled · Belgium
- Dec 19, 2016Phase 1 study in AsthmaNCT02999711 · 23 enrolled · United Kingdom
- Apr 4, 2017Phase 1 study in AsthmaNCT03112577 · 32 enrolled · United States, United Kingdom
- Nov 7, 20182 phase 2 studies in Dermatitis, AtopicNCT03736967, NCT03738423
- Dec 9, 2019Named itepekimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, REGN3500, SAR440340
TargetBeta
“Interleukin-33 inhibitor”ChEMBL 37, by rule
Other programs on IL33
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| GSK3862995B | GlaxoSmithKline | phase 2 | 5 |
| ompekimig | Pfizer | phase 2 | 3 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 5 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03738423Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Terminated | Mar 13, 2020 | 129 |
| NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more | 2 | Terminated | Mar 13, 2020 | 206 |
| NCT03112577Asthma · United States, United Kingdom | 1 | Completed | Mar 20, 2019 | 32 |
| NCT02999711Asthma · United Kingdom | 1 | Completed | Aug 30, 2018 | 23 |
| NCT02958436Healthy Volunteers · Belgium | 1 | Completed | Jun 18, 2017 | 40 |
How it is read
Names in the registry
- “Itepekimab (SAR440340)”, 7 entries
- “REGN3500”, 5 entries
- “Itepekimab SAR440340”, 3 entries
- “SAR440340”, 2 entries
Conditions, from the studies’ own filings
- Nasal Polyps, 5 studies
- Pulmonary Disease, Chronic Obstructive, 5 studies
- Asthma, 3 studies
- Dermatitis, Atopic, 2 studies
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.